Avid Bioservices Inc (CDMO)

[Protector]

cj, I have been thinking about what you wrote:

...what gets me about Dr. Birge is that this man's cancer lab of 10 or so at Rutgers has been working on “the eradication of cancer” for ~15yrs, and all of a sudden he hooks up with Dr. Brekken & Peregrine, and now he's heading to Istalbul in June to give a talk ICHC 2016, and this is the subject he chooses: “Phosphatidylserine is a Global Immunosuppressive Signal in Cell Death & Cancer”.

I had never looked at it that way because I wasn't very, or actually not, informed about what Dr. Birge has been doing the past 15yrs.

I'd like however, with hindsight and all the info we have received here on the IHub PPHM board, wonder more in depth about the WHY but also the HOW.

I think, and possibly RRDog can confirm that, that Dr. Birge as well as Rutgers have an iron reputation. That means that Dr. Birge when he, apparently, starts a road show that started in faculty then followed by some public appearances (e.g. PPHM's conference/round table) and now on the public forum at the ICHC 2016 and with the SAME TITLE “Phosphatidylserine is a Global Immunosuppressive Signal in Cell Death & Cancer” does NOT do such thing without FOR HIMSELF done the needed research to support his claims.

He will for sure have been in contact with Dr. Thorpe and Dr. Brekken because it is unthinkable that Dr. Bridge di, say, in one or two years all the needed research to make these claims on his own. Thorpe and Brekken have complete labs working on this.

This actually implies that Dr. Birge may have been involved in this from BEFORE CEO King mentioned his couple of dozen collaborations. As I wrote before, if you mention the collaborations they exist on, hence some before, the moment you can mention them as a fact.

And, Dr. Birge, as many others all of us included, will certainly be aware of the PII dose switching debacle and apparently just like Dr. Garnick must have gien it no more weight then just a bump in the road (as Garnick told us personally on a past annual meeting mingling). Dr. Birge must, just as Dr. Brekken confirmed at NYAS two years ago, have know that the PII results where BETTER then those presented on 7th Sept 2012.

A little detail, Dr. Birge uses CEO King's terminology (Global vs local) vs Brekken's (Upstream vs downstream). I'd propose 'Systemic' :) but then again, Hunt Managers have no say in that :)

By looking at all this in the above presented way, I think that Dr. Birge involvement is/will be much more important then we think. The man has something to loose by being wrong: his reputation.

Furthermore he is clearly on a mission here because as you emphasized he is taking his message out on the international forum.

Now what are the chances that in the same period of time another cancer research heavy weight, Dr. Wolchok from Memorial Sloan Kettering, with as much to loose at Dr. Brige, also embraces Phophotidylserine (PS) related research and clinical trials. Memorial Sloan Kettering has now officially been mentioned as the Early State Triple Native Breast Cancer clinical trial collaborator (Paclitaxel+Bavituximab).

So there must have been some chemistry behind the curtains that now results in world renound cancer researchers not only being pulled by PS related research but also get involved with PPHM and Bavituximab in public.

And of course, these are the new kids in PPHM town so no disrespect for Dr. Thorpe, Brekken, Antonia, Gabrilovich, etc who probably paved or helped pave this road with CEO King, Garnick and the others.